Zacks Investment Research upgraded shares of Cue Biopharma (NASDAQ:CUE) from a hold rating to a strong-buy rating in a report issued on Friday, Zacks.com reports. They currently have $10.00 price target on the stock.
According to Zacks, “Cue Biopharma, Inc. is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma, Inc. is headquartered in Cambridge, Massachusetts. “
Other equities analysts have also issued reports about the stock. Robert W. Baird assumed coverage on shares of Cue Biopharma in a research note on Thursday, July 25th. They issued an outperform rating and a $13.00 target price for the company. ValuEngine lowered shares of Cue Biopharma from a hold rating to a sell rating in a research note on Wednesday, November 13th.
Shares of CUE stock traded up $0.28 on Friday, hitting $9.08. The stock had a trading volume of 177,800 shares, compared to its average volume of 83,483. The firm has a market cap of $206.72 million, a P/E ratio of -4.68 and a beta of 1.21. The company has a current ratio of 3.17, a quick ratio of 3.17 and a debt-to-equity ratio of 0.10. Cue Biopharma has a twelve month low of $4.16 and a twelve month high of $9.94. The company has a fifty day moving average price of $8.11 and a two-hundred day moving average price of $8.05.
A number of hedge funds and other institutional investors have recently made changes to their positions in CUE. Russell Investments Group Ltd. acquired a new position in Cue Biopharma in the 3rd quarter worth $67,000. Strs Ohio boosted its stake in Cue Biopharma by 500.0% in the 2nd quarter. Strs Ohio now owns 15,000 shares of the company’s stock worth $134,000 after purchasing an additional 12,500 shares during the period. Sigma Planning Corp boosted its stake in Cue Biopharma by 13.6% in the 2nd quarter. Sigma Planning Corp now owns 47,805 shares of the company’s stock worth $430,000 after purchasing an additional 5,706 shares during the period. Rock Creek Group LP acquired a new position in Cue Biopharma in the 2nd quarter worth $447,000. Finally, Northern Trust Corp boosted its stake in Cue Biopharma by 2.0% in the 2nd quarter. Northern Trust Corp now owns 204,555 shares of the company’s stock worth $1,839,000 after purchasing an additional 3,970 shares during the period. 20.00% of the stock is owned by hedge funds and other institutional investors.
Cue Biopharma Company Profile
Cue Biopharma, Inc, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers.
Recommended Story: Day Trading – Risk Worth the Reward?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.